Results 21 to 30 of about 6,428 (208)

Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia

Journal of Obesity, 2011
Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population.
Changyu Pan, Hyung Joon Yoo, Low-Tone Ho
doaj   +1 more source

The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice

Frontiers in Pharmacology, 2019
Rimonabant was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was withdrawn from market due to the notably increased rates of psychiatric side effects.
Vincenzo Micale, Vincenzo Micale, Vincenzo Micale, Filippo Drago, Pia K. Noerregaard, Christian E. Elling, Carsten T. Wotjak   +6 more
doaj   +1 more source

Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia

Molecules, 2021
Alcohol consumption is associated with gut dysbiosis, increased intestinal permeability, endotoxemia, and a cascade that leads to persistent systemic inflammation, alcoholic liver disease, and other ailments.
Luis Santos-Molina, Alexa Herrerias, Charles N. Zawatsky, Ozge Gunduz-Cinar, Resat Cinar, Malliga R. Iyer, Casey M. Wood, Yuhong Lin, Bin Gao, George Kunos, Grzegorz Godlewski   +10 more
doaj   +1 more source

Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results [PDF]

, 2014
Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular ...
Erdozain, Amaia M, Jagerovic, Nadine, Erdozain, Amaia M., López-Moreno, José Antonio, Erdozain Fernández, Amaia Maite, Girón, Rocío, Rodríguez de Fonseca, Fernando, Meana Martínez, José Javier, Meana, J. Javier, Morales, Paula, Martín, M. Isabel, Martín, Isabel, Fernández Fernández, Cristina, López Moreno, José Antonio, Fernández Ruiz, Javier, Martín, M Isabel, Goya, Pilar, Fernández-Fernández, Cristina, Callado, Luis F., Callado Hernando, Luis Felipe, Sánchez, Eva, Callado, Luis F, Fernández-Ruiz, Javier, Meana, J Javier   +23 more
core   +1 more source

Comparison of rimonabant and sibutramine treatment effects on food compulsion in rats Comparação do efeito do rimonabanto e da sibutramina no tratamento da compulsão alimentar em ratos

Acta Cirúrgica Brasileira, 2009
PURPOSE: To compare the therapeutic effect of rimonabant, a new drug which is a selective antagonist of CB1 receptors, with the sibutramine. METHODS: It is an experimental clinical trial, prospective, placebo controlled. Our test was performed in 38 rats,
Honório Sampaio Menezes, Verônica Ciulla, Paulo Sampaio Camargo, Cora Albrecht Correa, Tatiana Medina Costa de Oliveira   +4 more
doaj   +1 more source

Rimonabant [PDF]

pharma-kritik, 2007
Ein Cannabinoid-Rezeptorblocker, der bei Adipösen die Gewichtsabnahme begünstigt. Ein Nutzen bei anderen Indikationen konnte bisher nicht gezeigt werden. Die Substanz kann verschiedene neuropsychiatrische Nebenwirkungen verursachen.
openaire   +1 more source

Quinacrine and rimonabant prolong the life span of Caenorhabditis elegans. [PDF]

Geroscience
Aging and age-related disorders are significant global health concerns, driving interest in potential preventative strategies. In this study, we established a high-throughput screening system to reveal the effects of quinacrine and rimonabant on lifespan
He Q, Guo S, Zhou A, Gong X, Cheng W, Ren H.   +5 more
europepmc   +2 more sources

Fatty acid flux and oxidation are increased by rimonabant in obese women. [PDF]

, 2012
This study aimed to determine in obese women if endocannabinoid receptor antagonism has effects on fatty acid and triglyceride metabolism and insulin sensitivity which are independent from the metabolic effects of weight loss.
Backhouse, Katharine, Russell-Jones, David, Frost, Gary S, Frost, G.S., Sarac, I., Russell-Jones, D., Umpleby, A. Margot, Robertson, M.D., Robertson, Denise M., Thomas, E. Louise, Shojaee-Moradie, Fariba, Wright, John, Umpleby, A.M., Shojaee-Moradie, F., Umpleby, A Margot, Thomas, E.L., Wright, J., Bell, Jimmy D, Bell, J.D., Sarac, Ivana, Frost, Gary S., Bell, Jimmy D., Stolinski, M., Stolinski, Michael, Backhouse, K., Thomas, E Louise, Robertson, M Denise   +26 more
core   +1 more source

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids

Frontiers in Pharmacology, 2018
Colorectal cancer (CRC), like other tumor types, is a highly heterogeneous disease. Within the tumor bulk, intra-tumoral heterogeneity is also ascribable to Cancer Stem Cells (CSCs) subpopulation, characterized by high chemoresistance and the unique ...
Donatella Fiore, Prashanthi Ramesh, Maria C. Proto, Chiara Piscopo, Silvia Franceschelli, Serena Anzelmo, Jan P. Medema, Maurizio Bifulco, Patrizia Gazzerro   +8 more
doaj   +1 more source

Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge

Cells, 2022
Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication development for treating substance use disorders (SUDs). Early studies indicated that rimonabant, a selective CB1R antagonist with an inverse agonist profile, was highly ...
Omar Soler-Cedeno, Zheng-Xiong Xi
doaj   +1 more source